In the ALS mouse model, researchers administered ASOs targeting ataxin-2 to the central nervous system of TDP-43 transgenic mice and found it could extend the survival rate (Becker et al., 2017). The gene discussed is ATXN2; the disease is amyotrophic lateral sclerosis.